No results for ‘’
Shukra Pharmaceuticals Ltd
₹30.98
(2.79%)
Mon, 15 Jun 2026, 00:11 pm
Health Technology
Pharmaceuticals: Major
24.5KShukra Pharmaceuticals Price to Cash Flow Ratio
| Particulars | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Price to earnings ratio | 37.35 | 12.62 | 1.79 | 19.29 | 99.91 |
| Price to book ratio | 0.45 | 0.58 | 2.03 | 6.20 | 15.23 |
| Price to sales ratio | 0.61 | 0.46 | 0.13 | 4.79 | 29.36 |
| Price to cash flow ratio | 11.93 | 1.26 | 2.65 | 0 | 108.69 |
| Enterprise value | 16.23Cr | 12.75Cr | 9Cr | 351Cr | 949Cr |
| Enterprise value to EBITDA ratio | 9.49 | 4.40 | 1.39 | 18.03 | 74.44 |
| Debt to equity ratio | 0.63 | 0.21 | 0.20 | 0.05 | 0.07 |
| Return on equity % | 0 | 4.70 | 21.16 | 44.70 | 15.90 |
Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio
The Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio is a key financial metric used by investors to evaluate Shukra Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Shukra Pharmaceuticals Ltd (NSE: , BSE: 524632) is currently trading at ₹30.98, with a market capitalization of ₹1395.52Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio is essential for fundamental analysis.
Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio Current Value
The current Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio stands at 108.69.
The latest Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio Historical Trend
The Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio has shown the following historical trend:
- 2024: 108.69
- 2023: 0
- 2022: 2.65
- 2021: 1.26
- 2020: 11.93
The recent rise in Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio suggests strengthening valuation trends and improving market sentiment.
What Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio Indicates for Investors
The Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/CF ratio indicates how much investors pay for company cash flow.
Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio Analysis Summary
The Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Shukra Pharmaceuticals Ltd Price to Cash Flow Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.